Therapeutic foam

• US 20090124704A1
• Filed: 05/12/2006
• Published: 05/14/2009
• Est. Priority Date: 05/13/2005
• Status: Active Grant

• Current Assignee: Boston Scientific Medical Device Limited (Boston Scientific Corporation)
• Original Assignee: BTG International Limited (Boston Scientific Corporation)
• Inventors: Jenkins, William John
• Granted Patent: US 8,703,827 B2
• Time in Patent Office: Days
• US Class Current: 514/723
• CPC Class Codes: A61K 31/08 acyclic, e.g. paraformaldehyde
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/122 Foams; Dry foams edible foams A61K9/0056
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

A foam for the treatment of varicose veins is disclosed, comprising a sclersosant solution, e.g. polidocanol, foamed with a gas mixture which includes greater than 41 % of a lipid soluble gas such as xenon. The aim is to provide a foam which may be injected into a varicose vein in large quantities because the gas component is dissipated quickly after the foam has acted on the varicose vein.

Claims

1. A foam comprising a liquid phase and a gas phase wherein the liquid phase comprises at least one sclerosing agent and the gas phase comprises between 41% and 100% of a gas which is lipid soluble.

2. A foam of claim 1 wherein the gas phase comprises between 50 and 100%, of gas which is lipid soluble.

3. A foam of claim 1 wherein the lipid soluble gas is a noble gas or mixture of noble gases.

4. A foam of claim 3 wherein the lipid soluble gas is argon, krypton or xenon or a mixture of two or more of these gases.

5. A foam of claim 1 wherein the remainder of the gas phase is substantially made up by oxygen, carbon dioxide or a mixture of oxygen and carbon dioxide.

6. A foam of claim 1 wherein the sclerosing agent is polidocanol solution.

7. A method of treating varicose veins comprising injecting into a vein in need thereof a foam of claim 1.

8. A method of claim 7 wherein substantially an entire greater saphenous vein is treated in one injection.

9. A method of claim 7 wherein between 15 ml and 50 ml of foam is injected.

10. A foam of claim 1 wherein the gas phase comprises between 60 and 100% of gas which is lipid soluble.

11. A foam of claim 1 wherein the gas phase comprises between 70 and 100% of gas which is lipid soluble.

12. A foam of claim 1 wherein the gas phase comprises between 80 and 100% of gas which is lipid soluble.

13. A foam of claim 1 wherein the gas phase comprises between 90 and 100% of gas which is lipid soluble.